Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon

被引:65
作者
Sieleunou, Isidore [2 ]
Souleymanou, Mohamadou [3 ]
Schoenenberger, Anne-Marie [3 ]
Menten, Joris
Boelaert, Marleen [1 ]
机构
[1] Inst Trop Med, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium
[2] Approved Treatment Ctr HIV AIDS, Maroua, Cameroon
[3] Dist Hosp, Pette, Cameroon
关键词
antiretroviral therapy; Africa; HIV/AIDS; treatment; survival analysis; FIXED-DOSE COMBINATION; RESOURCE-POOR SETTINGS; HIV-INFECTED PATIENTS; SOUTH-AFRICA; HIV-1-INFECTED PATIENTS; PROSPECTIVE COHORT; INCOME COUNTRIES; DRUG-RESISTANCE; EARLY MORTALITY; PILOT PROJECT;
D O I
10.1111/j.1365-3156.2008.02183.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
To analyse the outcomes of antiretroviral therapy (ART) in routine conditions in a rural hospital in the Far-North province of Cameroon. Retrospective cohort study of 1187 patients > 15 years who started ART between July 2001 and December 2006. The survival time was estimated by Kaplan-Meier analysis and Cox proportional hazard models were fitted to explain survival. Upon enrolment, 90.4% patients were in WHO stage III or IV and 56.1% had a BMI < 18.5. Median CD4 count was 105 cells/mm(3) (IQR 40-173). At the end of the study period, 338/1187 had died and 59/1187 were lost to follow-up. The survival probability was 77% at 1 year [95% CI: 75-80] and 47% at 5 years [95% CI: 40-55]. The median survival time was 58 months. CD4 count, haemoglobin, BMI, sex and clinical stage at enrolment were independent predictors of mortality. This study confirms the clinical benefit of ART programs in a remote and resource-constrained setting operating in routine conditions. The challenge ahead is to secure earlier access to ART and to maintain its longer-term benefit.
引用
收藏
页码:36 / 43
页数:8
相关论文
共 49 条
  • [1] Lessons learned from use of highly active antiretroviral therapy in Africa
    Akileswaran, C
    Lurie, MN
    Flanigan, TP
    Mayer, KH
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 (03) : 376 - 385
  • [2] [Anonymous], 2003, SCAL ANT THER RES LT
  • [3] Bekker LG, 2003, SAMJ S AFR MED J, V93, P458
  • [4] Bourgeois A, 2005, ANTIVIR THER, V10, P335
  • [5] Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2
  • [6] Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa
    Coetzee, D
    Hildebrand, K
    Boulle, A
    Maartens, G
    Louis, F
    Labatala, V
    Reuter, H
    Ntwana, N
    Goemaere, E
    [J]. AIDS, 2004, 18 (06) : 887 - 895
  • [7] Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa
    Coetzee, D
    Boulle, A
    Hildebrand, K
    Asselman, V
    Van Cutsem, G
    Goemaere, E
    [J]. AIDS, 2004, 18 : S27 - S31
  • [8] The price of adherence: Qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda
    Crane, J. T.
    Kawuma, A.
    Oyugi, J. H.
    Byakika, J. T.
    Moss, A.
    Bourgois, P.
    Bangsberg, D. R.
    [J]. AIDS AND BEHAVIOR, 2006, 10 (04) : 437 - 442
  • [9] Comparisons of causes of death and mortality rates among HIV-infected persons - Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras
    Crum, NF
    Riffenburgh, RH
    Wegner, S
    Agan, BK
    Tasker, SA
    Spooner, KM
    Armstrong, AW
    Fraser, S
    Wallace, MR
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (02) : 194 - 200
  • [10] Cohort profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts
    Dabis, F
    Balestre, E
    Braitstein, P
    Miotti, P
    Brinkhof, GM
    Schneider, M
    Schechter, M
    Laurent, C
    Boulle, A
    Kabugo, C
    Capkun, G
    Seyler, C
    McIntyre, J
    Sprinz, E
    Bansgberg, D
    Van der Borght, S
    Egger, M
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2005, 34 (05) : 979 - 986